Navigation Links
PTC Therapeutics Announces $25 Million Award From Cystic Fibrosis Foundation Therapeutics for Development of PTC124
Date:7/16/2008

"_new">http://www.cff.org ).

About PTC124

PTC124 is an orally delivered investigational new drug for the treatment of genetic disorders due to nonsense mutations. Nonsense mutations are single-point alterations in the genetic code that prematurely stop the translation process, preventing production of a functional protein. In Phase 2a clinical trials in nonsense-mutation-mediated cystic fibrosis (CF) and Duchenne muscular dystrophy (DMD), PTC124 has demonstrated the ability to produce protein across a variety of nonsense mutation types. Across all clinical studies to date, PTC124 has been generally well tolerated and has achieved target plasma concentrations that have been associated with activity in preclinical models. PTC124 is currently in Phase 2b development in DMD with the goal of demonstrating that increasing functional protein levels in patients with nonsense-mutation-mediated genetic disorders may provide clinical benefits.

About the Cystic Fibrosis Foundation

The Cystic Fibrosis Foundation, the leading organization focused on curing and controlling cystic fibrosis, has invested nearly $300 million in drug research with biotech companies since 1998 to develop therapies to fight CF. As a result, the Foundation has built a drug pipeline with more than 30 promising therapies in development. Virtually all the approved CF therapies available today were made possible because of the support of the Foundation. Based in Bethesda, MD, the Foundation has 80 chapters and branch offices, and supports and accredits a nationwide network of 115 CF care centers that provide treatment and vital resources to patients and families. For more information visit http://www.cff.org

About PTC Therapeutics Inc.

PTC is a biopharmaceutical company focused on the discovery, development and commercialization of orally administered, proprietary, small-molecule drugs that target post-transcriptiona
'/>"/>

SOURCE PTC Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Echo Therapeutics Announces Publication of Positive Clinical Data for its Symphony Transdermal Continuous Glucose Monitoring System in Journal of Diabetes Science and Technology
2. Nile Therapeutics Announces Dosing in Phase IIa Study of CD-NP in Heart Failure Patients
3. Echo Therapeutics Initiates Clinical Study of Its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes
4. Silence Therapeutics Announces Board Changes
5. Halozyme Therapeutics Announces That Chemophase Meets Primary Endpoint in Phase I/IIa Clinical Trial
6. Data Presented at American Headache Societys Annual Scientific Meeting Show Primary Endpoint Met as Well as Improvement on Important Secondary Endpoints in Phase IIb Acute Migraine Trial of TorreyPines Therapeutics Tezampanel
7. TorreyPines Therapeutics to Host Webinar at 11 a.m. EDT Today on the Opportunity for Treating Chronic Pain, Migraine and Muscle Spasticity Through Inhibition of Neurotransmitter Glutamate
8. CV Therapeutics Announces Archives of Internal Medicine Publication of Study Showing 20 Percent of Heart Attack Patients in Premier Registry Experienced Angina at One Year
9. Pilot Therapeutics Announces Relaunch as Gene Smart(TM) Health
10. Cell Therapeutics, Inc. (CTI) to Hold Conference Call to Discuss Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data
11. PTC Therapeutics Announces Data from Additional Clinical Studies of PTC124 in Cystic Fibrosis Confirming Activity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... Calif. , Jan. 14, 2014 The Brandeis Medical Center, ... Angeles a premier and affordable laser tattoo removal experience ... Dr. Brandeis, focus is in providing high quality cosmetic services with ... patients. " Southern California has seen ...
(Date:1/14/2014)... Animal Emergency Critical Care, a LifeCentre partner practice, located at ... is the first in Loudoun County to ... Susan M. Barnes , Medical Director, is a well-seasoned veterinarian ... Cole Taylor , are avid scuba divers. "As altitude skiers and ...
(Date:1/14/2014)... , Jan. 14, 2014   Oligomerix, Inc. , a privately ... for Alzheimer,s disease (AD) and related neurodegenerative disorders, announced ... Valhalla, NY as of January 15, ... at New York Medical College. Oligomerix, which ...
Breaking Medicine Technology:Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2Hyperbaric Veterinary Medicine (hvm) Announces Animal Emergency Critical Care Installs A Small Animal Hyperbaric Chamber 2Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College 2
... ALISO VIEJO, Calif., April 7, 2011 Avanir Pharmaceuticals, ... data from a number of clinical research activities will be ... of Neurology (AAN), taking place in Honolulu, HI, at the ... details about the data presentations:Title: Burden of Pseudobulbar Affect on ...
... Texas, April 7, 2011 Luminex Corporation (Nasdaq: ... Excellence Award in the category of In Vitro Diagnostics ... is a compact, versatile laboratory analysis platform designed to ... from a single sample. (Logo:   http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ...
Cached Medicine Technology:Avanir Pharmaceuticals to Present Data at the American Academy of Neurology Annual Meeting 2Avanir Pharmaceuticals to Present Data at the American Academy of Neurology Annual Meeting 3Avanir Pharmaceuticals to Present Data at the American Academy of Neurology Annual Meeting 4Luminex Corporation Wins Prestigious Medical Design Excellence Award 2Luminex Corporation Wins Prestigious Medical Design Excellence Award 3
(Date:4/23/2014)... The American Society for Radiation Oncology (ASTRO) has ... Radiation Therapy for Endometrial Cancer: An ASTRO Evidence-Based ... therapy in the treatment of endometrial cancer. The ... 2014 issue of Practical Radiation Oncology ... The full-length guideline is available as an open-access ...
(Date:4/23/2014)... A novel compound that targets an important brain ... cocaine addiction behaviors, including relapse behavior, a University at ... strong evidence that this may be a novel lead ... medications exist., The UB research was published as an ... , In the study, the compound, RO5263397, severely blunted ...
(Date:4/23/2014)... accessible detection methods that can rapidly screen a ... single cell inside that population has been seriously ... , In the Royal Society of Chemistry journal ... he and his coworkers have developed a novel ... protein ( Chem. Sci. , 2014, DOI: 10.1039/C4SC00578C, ...
(Date:4/23/2014)... In a country as wealthy as the United States, it ... do not have access to adequate food due to lack ... , Recent research at the University of Illinois using ... revealed that the seniors who are dealing with hunger are ... 2011, 8.35 percent of Americans over age 60 faced the ...
(Date:4/23/2014)... Leisure Time Physical Activity on Mobility Limitation in Old ... the risk of mobility limitation in old age, whereas ... in a study which followed up 5,200 public sector ... the Gerontology Research Center in Finland and the Finnish ... often repetitive, wears the body and lasts for several ...
Breaking Medicine News(10 mins):Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 2Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 3Health News:Novel compound halts cocaine addiction and relapse behaviors 2Health News:Following a protein's travel inside cells is key to improving patient monitoring, drug development 2Health News:More Americans in their golden years are going hungry 2Health News:Midlife occupational and leisure-time physical activity limits mobility in old age 2
... April 29 George W. Crabtree, a senior,scientist and ... Laboratory, was elected a member of the National Academy,of ... in the NAS is one of the highest honors ... Crabtree will be inducted into the Academy,next April during ...
... April 29 Warner,Chilcott Limited (Nasdaq: WCRX ) ... to settle a securities class action lawsuit pending,in the ... New York.,The suit asserted claims under the Securities Act ... those who were allegedly damaged as a result of,acquiring ...
... Children,s Hospital, SEATTLE, April 29 PEMCO ... its "Super-Long Coffee Order" promotion with,Tully,s Coffee. The ... coffee orders. PEMCO Insurance donates $1 to,Children,s Hospital ... The winners from the promotion,s third and fourth ...
... or more of blood can be life-threatening , , ... that thicken the blood are highly effective in ... University of California, San Diego, bioengineering researchers. , ... standard emergency treatment for patients with severe bleeding. ...
... quarter of those asked had borrowed, given away allergy ... News) -- If you,ve ever shared your allergy medicines, ... friend, you,ve got plenty of company: A new survey ... them from others. , However, this can be an ...
... from the American Cancer Society finds cancer survivors who ... fruits and vegetables, and getting adequate exercisehave higher health-related ... not follow such recommendations. The study, which appears in ... also finds cancer survivors have low rates of smoking, ...
Cached Medicine News:Health News:Argonne's Crabtree Elected to National Academy of Sciences 2Health News:Warner Chilcott Announces Settlement of Securities Litigation 2Health News:Warner Chilcott Announces Settlement of Securities Litigation 3Health News:PEMCO's Super-Long-Coffee-Order Contest Names Newest Winners 2Health News:Viscosity Enhancers Curb Bleeding Complications 2Health News:Many Americans Share Prescription Meds 2Health News:Cancer survivors who practice healthy habits have higher quality of life 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: